NYSE:EBS
Emergent BioSolutions Inc.
Emergent BioSolutions Inc.'s revenue fell 28.8% in fiscal 2025 to $742.9M while operating margin rose to 13.5%. Free cash flow was $156.8M, 21.1% of revenue, and the diluted share count rose 7.0%.Summary generated from Emergent BioSolutions Inc.'s SEC filings. Latest annual report filed Feb 27, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$742.9M
Revenue growth−28.8%
Revenue, 5-yr CAGR−14.0%
Gross margin56.1%
Operating margin13.5%
Net margin7.1%
ROIC6.4%
Return on equity10.5%
Debt / equity1.13
Free cash flow$156.8M
FCF margin21.1%
Share count change+7.0%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 1,774 | 1,118 | 1,049 | 1,044 | 743 |
| Operating income | 341 | −170 | −726 | −109 | 100 |
| Net income | 220 | −212 | −761 | −191 | 53 |
| Free cash flow | 96 | −150 | −258 | 36 | 157 |
Recent filings
- 4Insider transaction report
Oct 7, 2026 - 4Insider transaction report
Oct 5, 2026 - 8-KRegulation FD disclosure
Sep 14, 2026 - 8-KOther events
Sep 1, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 6, 2026 - 8-KResults of operations and financial condition
Aug 5, 2026 - 8-KEntry into a material agreement
Jun 29, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 1, 2026